Document is current

Article History

Received: 6 November 2024

Accepted: 19 March 2025

First Online: 25 March 2025

Declarations

:

: S.M. received honoraria for lectures from MSD, and Roche and support for travel from Johnson&Johnson, Intuitive Surgical and Distalmotion. A.W. received support for travel and honoraria for lectures from Roche, Eisai, Novartis, Pfizer, Lilly, Iomedica, Interplan, MSD, MCI, RCC and Menarini Stemline. A.W. participated on a Data Safety Monitoring Board of Iomedico and partipated in Advisory Boards of MSD, Roche, Novartis, Pfizer, Seagen, Lilly, Menarini Stemline and P. Fabre. A.W. participated the steering committee of the Breast Cancer and Gynecological Cancer Track of the AIO (Arbeitsgemeinschaft Internistische Onkologie) of the DKG (Deutsche Krebsgesellschaft) and was a member in the Consensus Conference Update S3-Guideline Breast Cancer of the DKG (Deutsche Krebsgesellschaft). H.-C.K. declares financial and non-financial support from Pfizer, Seagen, Novartis, Roche, Genomic Health/Exact Sciences, Amgen, AstraZeneca, Riemser, Carl Zeiss Meditec, TEVA, Theraclion, Janssen-Cilag, GSK, LIV Pharma, Lilly, SurgVision, Onkowissen, Gilead, Daiichi Sankyo, Stemline, Tesaro and MSD and owns stock of Theraclion SA. O.H. declares financial support from Eli Lilly, Roche, AstraZeneca, Amgen, Pfizer, Eisai, Gilead, Hexal, MSD, Novartis, Seagen und Daiichi Sankyo and Alpinion. O.H. is auditor for OnkoZert on behalf of the DKG (Deutsche Krebsgesellschaft). R.K. declares financial and non-financial support from Intuitive Surgical, Medtronic, Avatera, CMR Surgical, Active Surgical, Cava Robotics, Novocure, Medicaroid, GSK, MSD, Astra-Zeneca. S.K.-B. is a consultant for QIAGEN and was the PI for two independent research grants sponsored by Pfizer Pharma GmbH. C.K. received support for travel expenses from QIAGEN and was involved in the conduction of two independent research grants sponsored by Pfizer Pharma GmbH. All other authors declare no financial or non-financial competing interests.